Media headlines about C.R. Bard (NYSE:BCR) have been trending somewhat positive recently, Accern reports. The research firm ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. C.R. Bard earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned headlines about the medical instruments supplier an impact score of 46.5083219045405 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s rankings:
- DelMar Pharmaceuticals, Inc. (DMPI) has a value of $0.90 per share While CR Bard, Inc. (BCR) is stand at $319.68 – Stocks Gallery (stocksgallery.com)
- Investors should hold on Healthcare Stock: CR Bard, Inc. (BCR) – Street Observer (press release) (streetobserver.com)
- Sharon M. Luboff Sells 30,252 Shares of C.R. Bard, Inc. (BCR) Stock (americanbankingnews.com)
- Reviewing C.R. Bard (BCR) and Its Competitors (americanbankingnews.com)
Shares of C.R. Bard (BCR) opened at 322.00 on Friday. The firm’s 50-day moving average price is $320.00 and its 200-day moving average price is $305.05. The stock has a market cap of $23.40 billion, a price-to-earnings ratio of 42.27 and a beta of 0.58. C.R. Bard has a 12-month low of $203.63 and a 12-month high of $324.58.
C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The company had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter last year, the company posted $2.54 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, analysts forecast that C.R. Bard will post $11.81 EPS for the current fiscal year.
Several equities research analysts have weighed in on BCR shares. BidaskClub cut C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC restated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Thursday, September 14th. BMO Capital Markets restated a “hold” rating and set a $317.00 target price on shares of C.R. Bard in a research report on Tuesday, July 11th. Finally, Zacks Investment Research upgraded C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 target price for the company in a research report on Monday, July 31st. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $292.00.
In other news, insider John P. Groetelaars sold 23,687 shares of C.R. Bard stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the sale, the insider now directly owns 31,445 shares of the company’s stock, valued at approximately $10,022,464.85. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Sharon M. Luboff sold 30,252 shares of C.R. Bard stock in a transaction on Friday, September 29th. The stock was sold at an average price of $320.00, for a total transaction of $9,680,640.00. The disclosure for this sale can be found here. Company insiders own 0.80% of the company’s stock.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with MarketBeat.com's FREE daily email newsletter.